10-Q: United-Guardian Q2 Sales Plunge 16% Amid China Tariffs

United-Guardian, Inc. reported a significant decline in net sales and net income for the second quarter and first half of 2025, primarily driven by reduced demand for cosmetic ingredients in China due to tariffs and trade uncertainty.

Summary

• Net sales for the second quarter of 2025 decreased by $551,980 (16%) to $2,838,225 compared to $3,390,205 in Q2 2024.
• Net sales for the first half of 2025 decreased by $1,325,797 (20%) to $5,319,352 compared to $6,645,149 in H1 2024.
• Net income for Q2 2025 was $626,826, a 34.4% decrease from $956,225 in Q2 2024.
• Net income for H1 2025 was $1,187,721, a 36.9% decrease from $1,881,667 in H1 2024.
• Earnings per common share (basic and diluted) were $0.14 for Q2 2025, down from $0.21 in Q2 2024, and $0.26 for H1 2025, down from $0.41 in H1 2024.
• Cosmetic ingredient sales decreased by 37% in Q2 2025 and 52% in H1 2025, primarily due to softer demand in China and a major distributor (ASI) working off excess inventory.
• Pharmaceutical net sales increased by 3% in Q2 2025 and 11% in H1 2025, driven by a new customer for Renacidin.
• Medical lubricant sales decreased by 12% in Q2 2025 due to excess customer inventory in India, but increased by 12% in H1 2025 due to increased orders from a customer in China.
• Working capital decreased by $137,625 to $10,613,457 at June 30, 2025, from $10,751,082 at December 31, 2024.
• Cash provided by operating activities significantly decreased to $625,323 in H1 2025 from $1,968,250 in H1 2024.
• The company declared a cash dividend of $0.35 per share on January 27, 2025, and $0.25 per share on July 11, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in net sales and net income, primarily driven by external factors like tariffs and trade uncertainty impacting key markets. While there are some positive developments in other product lines and distribution, the overall financial performance is substantially weaker, and future risks related to trade policies remain high.

Positives

• Pharmaceutical net sales increased by 3% in Q2 2025 and 11% in H1 2025, driven by a new customer for Renacidin.
• Medical lubricant sales increased by 12% in H1 2025 due to increased orders from a customer in China.
• Net gain on marketable securities improved from a loss of $9,501 in Q2 2024 to a gain of $24,576 in Q2 2025, and increased from $31,995 to $36,926 for the six-month periods.
• The current ratio increased from 6.6 to 1 at December 31, 2024, to 6.7 to 1 at June 30, 2025, indicating strong liquidity.
• The company anticipates beginning manufacturing and reporting sales of its new Natrajel line of sexual wellness ingredients in the second half of 2025.
• Expanded distribution relationship with Azelis Group NV to include medical products in the UK and Ireland, and personal care products in South Korea.

Negatives

• Net sales decreased by 16% in Q2 2025 and 20% in H1 2025 compared to the prior year periods.
• Net income decreased by 34.4% in Q2 2025 and 36.9% in H1 2025 compared to the prior year periods.
• Earnings per share significantly declined from $0.21 to $0.14 in Q2 and from $0.41 to $0.26 in H1.
• Cosmetic ingredient sales, the largest product line, saw substantial decreases of 37% in Q2 and 52% in H1, primarily due to softened demand in China and distributor inventory adjustments.
• Cash provided by operating activities decreased significantly from $1,968,250 in H1 2024 to $625,323 in H1 2025.
• Investment income decreased by 29% in Q2 2025 and 22% in H1 2025 due to lower interest rates and reduced invested funds.
• Operating expenses increased by 15% in Q2 2025 and 13% in H1 2025, mainly due to higher sales and marketing, and payroll expenses.

Risks

• Significant tariffs or other restrictions on Chinese imports, or retaliatory measures by China, could materially and adversely affect business, financial condition, or results of operations.
• Tariffs may make products less cost-competitive and reduce gross margins, especially in China, where competition from Asian companies is significant.
• Inability to increase product prices sufficiently to offset tariffs could reduce demand in certain regions.
• Tariffs levied on finished products manufactured in China and imported into the U.S. could increase prices and impact demand.
• Customers may consider moving manufacturing from China as a strategic decision to limit tariff impact.
• Concentration of raw material suppliers, with three major suppliers accounting for approximately 85% of purchases in H1 2025 and two major suppliers accounting for 92% in Q2 2025.
• Reliance on one contract manufacturer for the pharmaceutical product Renacidin; any disruption could materially impact revenue.
• High customer concentration, with the largest cosmetic ingredient distributors and three pharmaceutical distributors accounting for 79% of Q2 2025 gross sales and 86% of outstanding accounts receivable.
• Significant change in the liquidity, financial position, or willingness to pay of any major customer could significantly impact results of operations and cash flows.
• Volatility of global financial markets could impact the investment portfolio.

Future Outlook

The company anticipates beginning manufacturing and reporting sales of its new Natrajel line of sexual wellness ingredients in the second half of 2025. The overall impact of recently imposed tariffs on trade partners, particularly China, remains uncertain and depends on factors such as duration, expansion, future changes to rates, retaliatory measures, and inflationary effects. Medicare Part D rebates for drug manufacturers are expected to increase due to a new program, with liabilities gradually increasing until full phase-in by 2031. The effective income tax rate is expected to remain at 21% for the current fiscal year. Working capital is believed to be sufficient for at least the next twelve months, with available cash and assets intended for organic growth, potential strategic transactions, and inflation mitigation. The company expects to continue dividend payments, purchase marketable securities, and pursue growth opportunities.

Management Comments

• We anticipate beginning manufacturing and revenue generation for our new Natrajel line of sexual wellness ingredients in the second half of 2025.
• We have expanded our relationship with Azelis Group NV to include medical products in the UK and Ireland, and South Korea as a new territory for our personal care product line.
• We are now pursuing an active strategy to significantly expand our distribution channels for all our products as well as new market segments globally.
• The decrease in cosmetic ingredient sales was due primarily to a net decrease of $556,243 (42%) in sales to ASI, attributed to softer demand from five significant customers in China due to trade uncertainty and tariffs, and Ashland working off excess inventory.
• The increase in gross pharmaceutical sales was primarily due to one of our larger distributors securing a new customer which increased their order quantity for Renacidin.
• The decrease in medical lubricant sales for the three-month period was primarily due to a decrease in orders from one of our larger customers in India, who stated the decrease was due to excess inventory.
• Our management and Board of Directors are continuing to closely monitor our investment portfolio and have made and will continue to make any changes they believe may be necessary or appropriate to minimize the future impact on our financial position that the volatility of the global financial markets may have.
• We believe that our working capital is, and will continue to be, sufficient to support our operating requirements for at least the next twelve months.

Industry Context

The company operates in the specialty chemical, pharmaceutical, and medical lubricant sectors. Its performance is significantly impacted by global trade policies, particularly tariffs imposed on China, which have led to softened demand for cosmetic ingredients in the Asian market. The pharmaceutical segment is navigating changes in government rebate programs, such as the new Medicare Part D Manufacturer Discount Program, which is expected to increase rebate liabilities for drug manufacturers over time. The company's strategic expansion of distribution channels and new product lines (Natrajel) indicates an effort to diversify and grow amidst these challenges.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards based solely on the filing's content is not possible.

Corporate Governance

Related Party Transactions

• Consulting agreement with Ken Globus, former President, expired on May 31, 2024; no payments were made in the threeand six-month periods ended June 30, 2025.
• Payments of $4,000 were made to PKF OConnor Davies for accounting and tax services during the six-month period ended June 30, 2025. Lawrence Maietta, a partner at PKF, is a director of the company.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in earnings per share and net income, though the company continued to pay dividends, including an increased dividend per share in Q1 2025 compared to Q1 2024, followed by a lower dividend in Q3 2025. The share price is likely to be negatively impacted by the poor financial results and ongoing tariff risks.
• Customers: Customers in China experienced softer demand due to trade uncertainty and tariffs, potentially leading to reduced product demand or price increases.
• Suppliers: The company faces concentration risk with three major raw material suppliers and one contract manufacturer for its key pharmaceutical product, Renacidin, which could impact supply stability.
• Employees: Payroll and payroll-related expenses increased, while accrued bonuses decreased in Q2 2025, indicating potential shifts in compensation structure.
• Creditors: The company maintains a strong current ratio (6.7 to 1) and sufficient working capital, suggesting a stable position to meet short-term obligations despite decreased cash from operations.

Next Steps

• Begin manufacturing and reporting sales of the new Natrajel line of sexual wellness ingredients in the second half of 2025.
• Monitor trade policy and tariff announcements, including potential retaliatory tariffs, and their impact on business.
• Continue to work with distributors to understand and manage the impact of tariffs on their business and joint customers.
• Make final payments of $10,814 for the building sprinkler system upgrade during the third quarter of 2025.
• Continue to use cash for dividend payments, purchase marketable securities, and take advantage of growth opportunities.

Key Dates

Recommendation

The company reported a substantial decline in net sales and net income, primarily due to adverse impacts from tariffs and softened demand in the crucial Chinese cosmetic ingredients market. While the company maintains strong liquidity and is expanding distribution channels for other product lines, the significant headwinds from trade policies and customer inventory adjustments present considerable uncertainty. The continued dividend payments offer some stability for existing shareholders, but the negative financial trends and ongoing risks suggest a cautious approach. A 'hold' recommendation is appropriate for investors to monitor how the company navigates these challenges and if its strategic initiatives can offset the current pressures.

Keywords

Specialty chemicals, Cosmetic ingredients, Pharmaceuticals, Medical lubricants, Sexual wellness ingredients, SEC filing, 10-Q, Financial results, Tariffs, China trade, Supply chain, Distribution agreement, Natrajel, Renacidin, United-Guardian